Side-by-side · Research reference
PT-141vsSemax
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AFDA-ApprovedReviewed13/41 cited
BHuman-MechanisticDraft12/39 cited
PT-141
MC4R Agonist · FDA-Approved (HSDD)
SQ · Abdomen / thigh · ≥45 min before sex
Semax
Cognitive enhancer · Russian Pharma
Intranasal · 2–3×/day during cognitive demand
01Mechanism of Action
Parameter
PT-141
Semax
Primary target
Melanocortin-4 receptor (MC4R) in hypothalamusSimerly 2023VYLEESI (bremelanotide injecti 2019
BDNF / NGF expression + monoamine modulationKaplan 2017
Pathway
MC4R agonism in paraventricular nucleus → autonomic + neuroendocrine sexual arousal pathwaysSimerly 2023
↑ BDNF + NGF synthesis + 5-HT modulation → neuroplasticity + anxiolysis + cognitive enhancementKaplan 2017
Downstream effect
Increased sexual desire and arousal; central rather than peripheral mechanismClayton 2015
Improved memory + attention; reduced anxiety; neuroprotection in ischemiaKaplan 2017
Feedback intact?
—
—
Origin
Cyclic 7-AA peptide derived from α-MSH (agonist Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-OH cyclic)VYLEESI (bremelanotide injecti 2019
Synthetic 7-AA peptide derived from ACTH(4-7) with C-terminal Pro-Gly-Pro stabilising tailKaplan 2017
Antibody development
—
—
02Dosage Protocols
Parameter
PT-141
Semax
Standard dose
1.75 mg SQVYLEESI (bremelanotide injecti 2019
Single dose ≥45 min before anticipated sexual activity. Max 1 dose / 24 hr.
200–600 mcg / dose intranasalKaplan 2017
Frequency
PRN, max 8 doses / month
2–3× per day during cognitive demand
Lower / starter dose
1 mg (off-label)
100 mcg / dose
Evidence basis
FDA-approved (HSDD pre-menopausal women)VYLEESI (bremelanotide injecti 2019Clayton 2015
Human-mechanistic + Russian clinicalKaplan 2017
Duration
PRN; reassess if no benefit after 8 doses
10–14 day cycles, repeated PRN
Reconstitution
Pre-filled commercial pen (Vyleesi). Research vial: bacteriostatic water.
Pre-formulated nasal spray (commercial); research vial: bacteriostatic water
Timing
≥45 min before sexual activity
Morning + early afternoon
04Side Effects & Safety
Parameter
PT-141
Semax
Flushing
Common, transient
—
Injection site reaction
Erythema, mild pain
—
Headache
Common
Uncommon, transient
Hyperpigmentation (focal)
Rare focal skin darkening; reversible after discontinuationVYLEESI (bremelanotide injecti 2019
—
Hypertension (transient)
Mean ↑6 mmHg systolic peaking ~4 h post-dose; resolves within 12 hVYLEESI (bremelanotide injecti 2019
—
Pregnancy / OB
Contraindicated
Avoid
Cardiovascular disease
Use caution; transient BP rise
—
Nasal irritation
—
Mild burning or congestion (transient)
Sleep disruption
—
Late-day dosing may interfere with sleep
Long-term safety
—
Limited Western RCT data
Absolute Contraindications
PT-141
- ·Uncontrolled hypertension
- ·Known cardiovascular disease (caution)
- ·Pregnancy
Semax
- ·Pregnancy / breastfeeding
Relative Contraindications
PT-141
- ·Pre-existing hyperpigmentation disorders
- ·MC4R-pathway-dependent psychiatric conditions
Semax
- ·Active psychiatric instability
- ·Concurrent strong stimulants
05Administration Protocol
Parameter
PT-141
Semax
1. Reconstitution
Vyleesi: pre-filled auto-injector. Research vial: 2 mL bacteriostatic water per 10 mg → 5 mg/mL.
Pre-formulated nasal spray (commercial) or research vial reconstituted with bacteriostatic water.
2. Injection site
SQ — abdomen or thigh.
Intranasal — 2–3 sprays per nostril per dose. Tilt head slightly back.
3. Timing
≥45 min before sexual activity for peak effect. Effect persists ~6–8 h.
Morning + early afternoon. Avoid evening (sleep disruption).
4. Storage
Vyleesi: room temp ≤30 °C. Research vial: refrigerate after reconstitution.
Refrigerate after reconstitution; light-protected.
5. Needle
Auto-injector (Vyleesi) or 29–31G, 4–8 mm insulin syringe.
Cycle on/off to avoid neurochemical adaptation.
06Stack Synergy
PT-141
— no documented stacks
Semax
+ Selank
ModerateSemax (cognitive enhancer, BDNF/NGF) and Selank (anxiolytic + immune) form the canonical Russian "neuro stack" — both intranasal peptide bioregulators with complementary axes. Semax for cognitive demand; Selank for stress mitigation.
- Semax
- 200–600 mcg intranasal · morning + afternoon
- Selank
- 150–300 mcg intranasal · midday + early evening
- Primary benefit
- Cognitive enhancement + stress mitigation